` NWBO (Northwest Biotherapeutics Inc) vs S&P 500 Comparison - Alpha Spread

NWBO
vs
S&P 500

Over the past 12 months, NWBO has underperformed S&P 500, delivering a return of -7% compared to the S&P 500's 11% growth.

Stocks Performance
NWBO vs S&P 500

Loading

Performance Gap
NWBO vs S&P 500

Loading
NWBO
S&P 500
Difference

Performance By Year
NWBO vs S&P 500

Loading
NWBO
S&P 500
Add Stock

Competitors Performance
Northwest Biotherapeutics Inc vs Peers

S&P 500
NWBO
ABBV
AMGN
GILD
VRTX
Add Stock

Northwest Biotherapeutics Inc
Glance View

Market Cap
358.9m USD
Industry
Biotechnology

Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. The company is headquartered in Bethesda, Maryland and currently employs 20 full-time employees. The company went IPO on 2001-12-14. The firm is focused on developing personalized immune therapies for cancer. The company has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The firm's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. The company has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. Its wholly owned subsidiaries include Flaskworks, Aracaris Ltd, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

NWBO Intrinsic Value
0.0578 USD
Overvaluation 79%
Intrinsic Value
Price
Back to Top